Probi appoints new CFO

Probi has appointed Henrik Lundkvist as CFO of Probi. He will start his assignment at the latest by the 7th of January, 2019.

Henrik joins Probi from GCE Group, a global manufacturer of gas control equipment, where he served as CFO since 2015. Prior to that he has held senior finance positions at E.ON Sverige AB and began his career as an auditor with EY.

“We are very happy to welcome Henrik to Probi as our new CFO. Together with our new CEO, Tom Rönnlund, and the whole management team, Probi is well-positioned for its next phase of growth and innovation. I also would like to thank Jörn Andreas who has done an excellent job during the period he served as CFO.”, says Chairman of the Board Jean-Yves Parisot.

“Probi is a leading player in the probiotic industry. The company has an innovative product portfolio and a strong financial position to compete successfully in a growing global market. I look forward to joining the team and to contributing to Probi´s path of profitable growth.”, says Henrik Lundkvist.


This information is information that Probi AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 8 November 2018 at 8.45 CET.

FOR FURTHER INFORMATION, CONTACT:
Jean-Yves Parisot, Chairman of the Board, Probi, tel +33 670 48 0684, e-mail: ir@probi.com

ABOUT PROBI
Probi AB is a Swedish publicly traded bioengineering company. The vision of Probi is to help people live healthier lives by delivering effective and well-documented probiotics, with proven health benefits based on scientific research. Founded by scientists in Sweden in 1991, Probi is a multinational company with four sites, active in more than 40 markets around the world and holding over 400 patents worldwide. In 2017, Probi had net sales of MSEK 612. The Probi share is listed on Nasdaq Stockholm, Mid Cap. Probi has about 5,000 shareholders. Read more at www.probi.com.

Tags:

About Us

Probi AB is a Swedish publicly traded biotechnology company that develops effective and well-documented probiotics. Through its research, Probi has created a strong product portfolio in the gastrointestinal health and immune system areas. The products are available to consumers in more than 40 countries worldwide. The customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. The Probi share is listed on NASDAQ OMX Stockholm, Mid-cap. Read more on www.probi.se.

Subscribe

Documents & Links